Jack Hidary, CEO of SandboxAQ, says the firm's partnership with Sanofi aims to drive biomarker discovery in clinical ...

Sanofi’s BTK inhibitor rilzabrutinib helped 23% of adults with a rare autoimmune blood disorder achieve target platelet counts in a Phase 3 trial, compared to zero patients in the placebo ...

Sanofi announced that it has entered into exclusive negotiations with the US private equity firm Clayton, Dubilier & Rice (CD&R) to transfer around 50% controlling stake in Opella.

As Sanofi prepares to halt U.S. marketing of its dengue vaccine in 2026, locally acquired infections in the country are ...

On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...

Drugmakers had hoped that inhibiting receptor-interacting protein kinase would decrease inflammation and reduce neuronal degeneration in patients with multiple sclerosis and other neurodegenerative co ...

Sanofi attributed its double-digit growth to growth in vaccines, particularly its latest flu jab. Another major revenue ...

Sanofi is nearing a sale of a 50% stake in its consumer unit, valued at 16 billion euros in total, to boost clinical trials ...

BEIJING, Nov. 5 (Xinhua) -- The China International Import Expo (CIIE) is a world-class platform for global enterprises to collaborate on development, said Shi Wang, president of Sanofi Greater China, ...

On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), ...

In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Sell rating on Sanofi (SNYNF – Research Report), with a ...